Cholinesterase predicts poor prognosis in patients with nonfatal acute exacerbation of COPD
Description
Data were compiled from the electronic medical record system of Wuhu Hospital of Traditional Chinese Medicine from January 2017 to December 2021. It contains the serum level of ChE, C-reactive protein (CRP), and biochemistry (albumin, blood urea nitrogen (BUN), creatinine), The clinical information of AECOPD patients (sex; age; medical history (diabetes mellitus, hypertension, coronary heart disease, heart failure); number of acute exacerbations in the previous 12 months); treatment-related data (whether patients received NIV or invasive mechanical ventilation, whether patients were admitted to the intensive care unit (ICU), and DoHS); results of arterial blood-gas analyses (partial pressure of carbon dioxide (pCO2), pH, lactic acid, and Oxygenation Index (OI)); D-dimer level; complete blood count (neutrophil-to-lymphocyte ratio (NLR), hematocrit, red blood cell distribution width (RDW), platelet-to-lymphocyte ratio (PLR), and platelet distribution width (PDW)). Our goal is to investigate the relationship between the serum cholinesterase (ChE) level and adverse clinical outcomes, including hypoxemia severity, hypercapnia, duration of hospital stay (DoHS), and noninvasive ventilation (NIV) requirement, in patients with AECOPD.